期刊
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
卷 1874, 期 1, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.bbcan.2020.188391
关键词
Lenvatinib; HCC; Molecular mechanisms; Clinical efficacy; Precision medicine
资金
- National Research Program of China [2017YFA0505803, 2017YFC0908100]
- state Key project for Infectious Diseases [2018ZX10732202-001]
- National Natural Science Foundation of China [81790633, 81672860, 61922047, 81422032, 81902412]
- National Natural Science Foundation of Shanghai [17ZR143800]
Lenvatinib, a multi-target tyrosine kinase inhibitor (TKI), is an emerging first-line therapy for hepatocellular carcinoma (HCC). Its application has changed the status of sorafenib as the only first-line TKI treatment for HCC for more than a decade. Evidence has shown that lenvatinib possesses antitumor proliferation and immunomodulatory activity in preclinical studies. In comparison, lenvatinib was non-inferior to sorafenib in overall survival (OS), and even shows superiority with regard to all the secondary efficacy endpoints. Immune-checkpoint inhibitors(ICIs)are now being incorporated into HCC treatment. Positive outcomes have been achieved in the combination of lenvatinib plus ICIs, bringing broader prospects for HCC. This review presents an overview on the therapeutic mechanisms and clinical efficacy of lenvatinib in HCC, and we discuss the future perspectives of lenvatinib in HCC management with focus on biomarker-guided precision medicine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据